References

Executive Summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis

10.1016/j.kint.2023.09.001 · 2024 · External reference

Lupus Nephritis

10.1038/s41572-025-00653-y · 2025 · External reference

2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis

10.1002/art.43212 · 2025 · External reference

The 2024 APLAR Consensus on the Management of Lupus Nephritis

10.1111/1756-185x.70021 · 2025 · External reference

Current Treatment of Lupus Nephritis: An Overview of the New Guidelines

10.1590/2175-8239-jbn-2025-0092en · 2025 · External reference

Lupus Nephritis: Redefining the Treatment Goals

10.1016/j.kint.2024.10.018 · 2025 · External reference

Real‐World Burden of Immunosuppressant‐Treated Lupus Nephritis: A German Claims Database Analysis

10.1007/s40744-023-00623-4 · 2024 · External reference

Lupus Nephritis Randomised Controlled Trials: Evidence Gaps and Under‐Represented Groups

10.1136/lupus-2024-001331 · 2024 · External reference

Progress of Rituximab in the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis

10.3389/fmed.2024.1472019 · 2024 · External reference

Anti‐CD20 Therapy in Lupus Nephritis: A Revisit

10.1515/rir-2025-0009 · 2025 · External reference

Rituximab in the Real‐World Treatment of Lupus Nephritis: A Retrospective Cohort Study in Japan

10.1093/mr/roac007 · 2023 · External reference

Rituximab as Add‐On Therapy in Patients With Resistant Lupus Nephritis Who Have Failed Induction or Maintenance Therapy With Other Agents: A Real‐World Experience From a Single Center in Mumbai

10.1177/09612033231219354 · 2024 · External reference

Efficacy and Safety of Voclosporin Versus Placebo for Lupus Nephritis (AURORA 1): A Double‐Blind, Randomised, Multicentre, Placebo‐Controlled, Phase 3 Trial

10.1016/s0140-6736(21)00578-x · 2021 · External reference

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis

10.1056/nejmoa2410965 · 2025 · External reference

Efficacy and Safety of Rituximab in Patients With Lupus Nephritis: A Systematic Review and Meta‐Analysis

10.5414/cn111197 · 2025 · External reference

Effectiveness and Safety of B Cell‐Targeting Biologics in the Treatment of Lupus Nephritis: A Systematic Review and Network Meta‐Analysis

10.1080/0886022x.2024.2416605 · 2024 · External reference

The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews

10.1136/bmj.n71 · 2021 · External reference

PRISMA 2020 Explanation and Elaboration: Updated Guidance and Exemplars for Reporting Systematic Reviews

10.1136/bmj.n160 · 2021 · External reference

Methodological Index for Non‐Randomized Studies (Minors): Development and Validation of a New Instrument

10.1046/j.1445-2197.2003.02748.x · 2003 · External reference

Quantifying Heterogeneity in a Meta‐Analysis

10.1002/sim.1186 · 2002 · External reference

Bias in Meta‐Analysis Detected by a Simple, Graphical Test

10.1136/bmj.315.7109.629 · 1997 · External reference

Long‐Term Efficacy of Anti‐CD20 Antibodies in Refractory Lupus Nephritis

10.1007/s00296-010-1755-0 · 2012 · External reference

Longterm Clinical and Immunological Effects of Anti‐CD20 Treatment in Patients With Refractory Systemic Lupus Erythematosus

2008 · External reference

Favorable Outcomes for Patients With Refractory Systemic Lupus Erythematosus Treated With Rituximab as Evidenced With a Follow‐Up of ≥ 10 Years: A Real‐World Evidence Study

10.1007/s00296-025-05879-3 · 2025 · External reference

Rituximab Treatment in Lupus Nephritis Resistant to Conventional Therapy: A Single‐Centre Experience

10.31138/mjr.250124.rtl · 2025 · External reference

Long‐Term Efficacy and Safety of Rituximab in Refractory and Relapsing Systemic Lupus Erythematosus

10.1093/ndt/gfq256 · 2010 · External reference

Histopathologic and Clinical Outcome of Rituximab Treatment in Patients With Cyclophosphamide‐Resistant Proliferative Lupus Nephritis

10.1002/art.22505 · 2007 · External reference

Effect of Rituximab on Serum Levels of Anti‐C1q and Antineutrophil Cytoplasmic Autoantibodies in Refractory Severe Lupus Nephritis

10.1007/s12013-014-0437-z · 2015 · External reference

Rituximab and Mycophenolate Mofetil for Relapsing Proliferative Lupus Nephritis: A Long‐Term Prospective Study

10.1093/ndt/gfp002 · 2009 · External reference

Outcomes With the Use of Rituximab in Patients With Refractory Lupus Nephritis in a Colombian Cohort

10.1016/j.rcreue.2022.07.006 · 2024 · External reference

Efficacy and Safety of Off‐Label Use of Rituximab in Refractory Lupus: Data From the Italian Multicentre Registry

2015 · External reference

Efficacy and Safety of Rituximab Biosimilar in Refractory Lupus

10.1136/lupus-2020-000442 · 2020 · External reference

Rituximab in the Treatment of Resistant Lupus Nephritis: Therapy Failure in Rapidly Progressive Crescentic Lupus Nephritis

10.1177/0961203313483376 · 2013 · External reference

Cyclophosphamide Versus Mycophenolate Versus Rituximab in Lupus Nephritis Remission Induction: A Historical Head‐To‐Head Comparative Study

10.1097/rhu.0000000000000760 · 2019 · External reference

Rituximab Is an Effective Treatment for Lupus Nephritis and Allows a Reduction in Maintenance Steroids

10.1093/ndt/gfp336 · 2009 · External reference

Rituximab Treatment in Resistant Lupus Nephritis: A Single‐Center Prospective Study

10.5414/cn111104 · 2024 · External reference

Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single‐Center Cohort Study in Korea

10.4078/jrd.2022.29.1.22 · 2022 · External reference

Long‐Term Follow‐Up in Lupus Nephritis Patients Treated With Rituximab‐Clinical and Histopathological Response

10.1093/rheumatology/kes348 · 2013 · External reference

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis

10.1002/art.41466 · 2021 · External reference

Long‐Term Kidney Outcome of Lupus Nephritis by Renal Response Status

10.1016/j.ekir.2024.09.028 · 2024 · External reference

Renal Response Status to Predict Long‐Term Renal Survival in Patients With Lupus Nephritis: Results From the Toronto Lupus Cohort

10.1136/lupus-2024-001264 · 2024 · External reference

Risk of Chronic Kidney Disease in 260 Patients With Lupus Nephritis: Analysis of a Nationwide Multicentre Cohort With up to 35 Years of Follow‐Up

10.1093/rheumatology/keae236 · 2025 · External reference

Renal Outcomes in the Long‐Term Follow‐Up of Lupus Nephritis

10.1590/2175-8239-jbn-2024-0118en · 2025 · External reference

Management of Lupus Nephritis: New Treatments and Updated Guidelines

10.34067/kid.0000000000000230 · 2023 · External reference

Refractory Lupus Nephritis: Current Understanding and Emerging Treatment Strategies

10.1007/s10238-025-02014-1 · 2025 · External reference